JXF吉祥坊

invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has successfully completed the acquisition of F-star Therapeutics, Inc. (“F-star”) (NASDAQ: FSTX) a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share).

On February 20, Sino Biopharm (HKE.01177) announced that Liamprost tablet (brand name: Kelitone ®), a treatment for lumbar spinal stenosis developed by its subsidiary of Beijing Tide, has been approved by the National Medical Products Administration (NMPA). Miss Tse, Theresa Y Y, chairwoman of the board of directors of Sino Biopharm, said dealing with an aging population has been elevated as a national strategy in the 2022 Government Work

On February 10, Sino Biopharm announced that its self-developed Class 1 new drug, TQB2103 (Claudin18.2 ADC), has submitted an application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration, PRC for clinical trials and has been accepted.

On January 29th, Sino Biopharm and its subsidiary CTTQ signed an investment framework agreement with the Administrative Committee of Guangzhou Development Zone to invest in the construction of the Southern headquarters and overseas pharmaceutical innovation center in the area. Lin Keqing, Party Secretary of Guangzhou Municipality, Guo Yonghang, Mayor of Guangzhou Municipality,

As a leading innovative R&D-driven pharmaceutical group in China, Sino Biopharm has always adhered to the three principles of "for the country, for the people and for the company" to guide its operation and development. At the recently held 2022 CEO Conference, Miss Tse, Theresa Y Y, Chairwoman of the Board of Directors of Sino Biopharm, and Mr. Tse, Eric S Y, Chief Executive Officer of Sino Biopharm, jointly unveiled the corporate culture of Sino Biopharm,

On October 14, 2022, well-known pharmaceutical industry media E Pharmaceutical managers and China's leading independent corporate and society responsibility consulting agency BizDao Consulting jointly released the "ESG Competitiveness and ESG Investment Value List of Chinese pharmaceutical Listed Enterprises". With its excellent ESG management performance and outstanding industry competitiveness,

On November 2, Sino Biopharm (01177.HK) announced that in the third quarter of 2022, as the pandemic situation in China was under control and normal production and life order was restored, medical consumption and in-hospital treatment volume recovered significantly, and the Group timely seized the opportunity to accelerate the progress of research and development, production and sales, driving the Group to achieve rapid recovery growth in the third quarter of 2022. In the third quarter of 2022

Recently, the series of "2022 China Top 100 Biopharmaceutical List" launched by Times Media Group has been launched one after another, and on October 24, its sub-list "Top 20 Competitive Chemical and Pharmaceutical Enterprises in China in 2022" was released, and Sino Biopharm was ranked fourth.

Recently, CP Pharmaceutical Group and Sino Biopharm held the 2022 CEO Conference, where representatives from Group headquarters, Chia tai Tianqing, Beijing Tide, Nanjing Chia tai Tianqing, Chia tai Qingdao, Chia tai Fenghai, Chia tai Qingjiang, invoX and other subsidiaries gathered to stimulate thinking and share wisdom.

On September 16, 2022, the "ESG Forum for Pharmaceutical and Health Industry and the Online Launch Meeting of the ESG Management Code for Pharmaceutical and Health Industry" hosted by the China Pharmaceutical Industry Association was successfully held. The conference brought together leading institutions and enterprises in China's economic, financial, pharmaceutical and health industries,